Cinobufagin Is a Selective Anti-Cancer Agent against Tumors with EGFR Amplification and PTEN Deletion

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Glioblastoma multiforme (GBM) is a highly malignant brain tumor.
• EGFR-driven tumors with PTEN deficiency often exhibit resistance to EGFR-targeted therapies.
• Identifying novel therapeutic compounds for EGFR-driven cancers is crucial.

Purpose of the Study:

• To screen Traditional Chinese Medicine compounds for activity against EGFR-amplified GBM.
• To evaluate the efficacy of cinobufagin in preclinical cancer models.
• To elucidate the mechanism of action of cinobufagin on EGFR signaling.

Main Methods:

• Screening of over 600 Traditional Chinese Medicine compounds against EGFR-amplified GBM cells.
• In vitro assays to assess cell proliferation, apoptosis, and cytotoxicity.
• In vivo studies using subcutaneous and intracranial U87MG-EGFR xenograft mouse models.

Main Results:

• Cinobufagin significantly inhibited proliferation in EGFR-amplified GBM cells and enhanced effects with PTEN deficiency.
• Cinobufagin demonstrated potent anti-proliferative activity against various EGFR-expressing carcinoma cell lines.
• The compound blocked EGFR phosphorylation and downstream signaling, inducing apoptosis and suppressing tumor growth in vivo.
• Cinobufagin treatment increased median survival in mice with intracranial U87MG-EGFR tumors.

Conclusions:

• Cinobufagin is a potent inhibitor of EGFR-driven cancer cell proliferation.
• The compound acts by blocking EGFR signaling, inducing apoptosis, and suppressing tumor growth.
• Cinobufagin represents a potential therapeutic candidate for malignant glioma and other EGFR-expressing human cancers.